Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...
How does Viking's weight loss med compare to ones from Novo, Eli Lilly?
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Eli Lilly plans to begin advertising weight-loss drug Zepbound
Eli Lilly (LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...
New health care policy changes will soon affect weight-loss drugs
Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling
Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to ...
Why compounders and telehealth providers are undeterred by the potential end of the weight-loss drug shortage
Online health platforms continue to advertise access to copycat versions of blockbuster weight-loss drugs Wegovy and Zepbound ...
Eli Lilly gets nod to sell weight-loss drug in Hong Kong by year-end - report
Learn how to grow your wealth through smart investing strategies and financial planning in this informative article by a ...
Novo Nordisk’s Stock Rises As Weight Loss Drug Sales Accelerate
Shares of Novo Nordisk (NVO) are up 8% in European trading after the Danish pharmaceutical company posted financial results ...